Physician profile
Arsh Singh
NPI 1063712826
$7,974.16
in general payments reported to CMS, 2019-2025
65 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.50 · 2020: $655 · 2021: $695 · 2022: $781 · 2023: $1,051 · 2024: $1,909 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,669 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.69 |
| Education | $117.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $746.17 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $726.68 | 2020-2025 | Tecvayli, Darzalex, Talvey |
| Celgene Corporation | $536.07 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $527.39 | 2021-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $432.27 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $355.40 | 2022-2025 | Piqray, Kisqali |
| Pfizer INC. | $323.00 | 2020-2025 | |
| Gilead Sciences, INC. | $307.98 | 2021-2025 | Trodelvy |
| Seagen INC. | $248.89 | 2020-2025 | Tukysa, Padcev |
| Glaxosmithkline, LLC. | $243.74 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $243.10 | 2020-2025 | Xospata, Padcev, Xtandi |
| Incyte Corporation | $234.04 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Beigene USA, INC. | $197.32 | 2020-2024 | Brukinsa, Tevimbra |
| Astrazeneca Pharmaceuticals LP | $195.39 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $178.75 | 2024 | Fruzaqla, Alunbrig, Ninlaro |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arsh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.